Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
Authors' conclusion
The combination of adherent exercise and liraglutide treatment reduced metabolic syndrome severity, abdominal obesity, and inflammation and may therefore reduce cardiometabolic risk more than the individual treatments.
Study context
- Population
- Adults with obesity without diabetes who lost 12% body weight on an 8-week low-calorie diet (800 kcal/day)130 per-protocol analysed
- Participants
- 195 adults
- Comparison
- Exercise, liraglutide or exercise + liraglutide vs placebo after diet-induced weight loss
- Primary endpoint
- Prespecified secondary outcome: metabolic syndrome severity z-score (MetS-Z)
- Follow-up
- One year
Methodological detailsdouble-blind, placebo-controlled, 4-arm, 166 participants completed the trial
- Double-blind
- Placebo-controlled
- 4-arm
- 166 participants completed the trial
Primary result
As reported in the abstract
MetS-Z change vs placebo
Liraglutide
- 0.37
95% CI - 0.58 to - 0.16P < 0.001
Combination
- 0.48
95% CI - 0.70 to - 0.25P < 0.001
Secondary outcomes
| Outcome | Estimate | P value |
|---|---|---|
| Abdominal fat percentage (android fat, DXA) · one yearExercise vs Placebo · lower with Exercise | decrease 2.6 percentage points | |
| Abdominal fat percentage (android fat, DXA) · one yearLiraglutide vs Placebo · lower with Liraglutide | decrease 2.8 percentage points | |
| Abdominal fat percentage (android fat, DXA) · one yearCombination vs Placebo · lower with Combination | decrease 6.1 percentage points | |
| hsCRP · one yearCombination vs Placebo · lower with Combination | decrease 43% | P = 0.03 |
High-sensitivity C-reactive protein (hsCRP) · one year
- hsCRP decreased only in the combination group vs placebo
Original publication
Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. Published 25 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →